{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:22Z","timestamp":1793383042480,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T00:00:00Z","timestamp":1271376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11926-010-0101-6","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T03:57:45Z","timestamp":1271303865000},"page":"198-203","source":"Crossref","is-referenced-by-count":100,"title":["Dermatomyositis and Type 1 Interferons"],"prefix":"10.1007","volume":"12","author":[{"given":"Steven A.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,16]]},"reference":[{"key":"101_CR1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/WCO.0b013e3283311ddf","volume":"22","author":"SA Greenberg","year":"2009","unstructured":"Greenberg SA: Inflammatory myopathies: disease mechanisms. Curr Opin Neurol 2009, 22:516\u2013523.","journal-title":"Curr Opin Neurol"},{"key":"101_CR2","doi-asserted-by":"crossref","unstructured":"Greenberg SA: Type 1 interferons and myositis. Arthritis Res Ther 2010, 12(Suppl 1):S4.","DOI":"10.1186\/ar2885"},{"key":"101_CR3","unstructured":"\u2022\u2022 Salajegheh M, Kong SK, Pinkus JL, et al.: Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010, 67:53\u201363. This study demonstrates the remarkable specificity of a high abundance of ISG15 transcript for dermatomyositis muscle, that ISG15 protein is conjugated to multiple other proteins in dermatomyositis muscle, and that the exposure of muscle cell culture to type 1 interferons produces a molecular picture highly similar to that of human dermatomyositis muscle."},{"key":"101_CR4","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archneur.60.5.780","volume":"60","author":"TD Levine","year":"2003","unstructured":"Levine TD: History of dermatomyositis. Arch Neurol 2003, 60:780\u2013782.","journal-title":"Arch Neurol"},{"key":"101_CR5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","volume":"1184","author":"AL Mammen","year":"2010","unstructured":"Mammen AL: Dermatomyositis and polymyositis. Ann N Y Acad Sci 2010, 1184:134\u2013153.","journal-title":"Ann N Y Acad Sci"},{"key":"101_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.29.1.67","volume":"29","author":"WL Norton","year":"1970","unstructured":"Norton WL, Velayos E, Robison L: Endothelial inclusions in dermatomyositis. Ann Rheum Dis 1970, 29:67\u201372.","journal-title":"Ann Rheum Dis"},{"key":"101_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00005072-197501000-00005","volume":"34","author":"BQ Banker","year":"1975","unstructured":"Banker BQ: Dermatomyostis of childhood, ultrastructural alteratious of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975, 34:46\u201375.","journal-title":"J Neuropathol Exp Neurol"},{"key":"101_CR8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1212\/WNL.26.10.952","volume":"26","author":"S Carpenter","year":"1976","unstructured":"Carpenter S, Karpati G, Rothman S, Watters G: The childhood type of dermatomyositis. Neurology 1976, 26:952\u2013962.","journal-title":"Neurology"},{"key":"101_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","volume":"94","author":"M Visser De","year":"1989","unstructured":"De Visser M, Emslie-Smith AM, Engel AG: Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989, 94:181\u2013192.","journal-title":"J Neurol Sci"},{"key":"101_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","volume":"48","author":"JT Kissel","year":"1991","unstructured":"Kissel JT, Halterman RK, Rammohan KW, Mendell JR: The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991, 48:26\u201330.","journal-title":"Arch Neurol"},{"key":"101_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329\u2013334.","journal-title":"N Engl J Med"},{"key":"101_CR12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","volume":"27","author":"AM Emslie-Smith","year":"1990","unstructured":"Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343\u2013356.","journal-title":"Ann Neurol"},{"key":"101_CR13","doi-asserted-by":"crossref","unstructured":"\u2022 Greenberg SA: Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008\u20132019. This review of dermatomyositis, polymyositis, and inclusion body myositis disease mechanism outlines a model of myofiber injury stemming directly from the intracellular production of type 1 interferons.","DOI":"10.1212\/01.WNL.0000291619.17160.b8"},{"key":"101_CR14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00019052-200406000-00018","volume":"17","author":"SA Greenberg","year":"2004","unstructured":"Greenberg SA, Amato AA: Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004, 17:359\u2013364.","journal-title":"Curr Opin Neurol"},{"key":"101_CR15","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sontheimer RD: Lichenoid tissue reaction\/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009, 129:1088\u20131099. This is a review of a class of disorders characterized by lichenoid tissue reactions.","DOI":"10.1038\/jid.2009.42"},{"key":"101_CR16","doi-asserted-by":"crossref","unstructured":"\u2022 Crowson AN, Magro CM, Mihm MC Jr: Interface dermatitis. Arch Pathol Lab Med 2008, 132:652\u2013666. The use of the term interface dermatitis is described, and skin diseases with this pathology are reviewed.","DOI":"10.5858\/2008-132-652-ID"},{"key":"101_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0046-8177(96)90132-X","volume":"27","author":"AN Crowson","year":"1996","unstructured":"Crowson AN, Magro CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996, 27:15\u201319.","journal-title":"Hum Pathol"},{"key":"101_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Wenzel J, Tuting T: An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis.\u201d J Invest Dermatol 2008, 128:2392\u20132402. This review advocates for a general role of type 1 interferons in many skin disorders characterized by an interface dermatitis. It advocates for a mechanism by which type 1 interferons exert their injurious effects through activation of cytotoxic T cells.","DOI":"10.1038\/jid.2008.96"},{"key":"101_CR19","doi-asserted-by":"crossref","unstructured":"\u2022 Greenberg SA, Fiorentino D: Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol 2009, 160:464\u2013465. This brief letter notes that perifascicular atrophy in dermatomyositis muscle has the same topology as the lichenoid tissue reaction in skin.","DOI":"10.1111\/j.1365-2133.2008.08967.x"},{"key":"101_CR20","first-page":"638","volume":"52","author":"PM Grimley","year":"1985","unstructured":"Grimley PM, Davis GL, Kang YH, et al.: Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab Invest 1985, 52:638\u2013649.","journal-title":"Lab Invest"},{"key":"101_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/01913128609015565","volume":"10","author":"J Kuyama","year":"1986","unstructured":"Kuyama J, Kanayama Y, Mizutani H, et al.: Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastruct Pathol 1986, 10:77\u201385.","journal-title":"Ultrastruct Pathol"},{"key":"101_CR22","first-page":"584","volume":"58","author":"D Feldman","year":"1988","unstructured":"Feldman D, Goldstein AL, Cox DC, Grimley PM: Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2\u2032,5\u2032 oligoadenylate synthetase induction. Lab Invest 1988, 58:584\u2013589.","journal-title":"Lab Invest"},{"key":"101_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(83)91771-3","volume":"1","author":"SA Rich","year":"1983","unstructured":"Rich SA, Owens TR, Bartholomew LE, Gutterman JU: Immune interferon does not stimulate formation of alpha and beta interferon induced human lupus-type inclusions. Lancet 1983, 1:127\u2013128.","journal-title":"Lancet"},{"key":"101_CR24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, et al.: Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664\u2013678.","journal-title":"Ann Neurol"},{"key":"101_CR25","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Walsh RJ, Kong SW, Yao Y, et al.: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784\u20133792. This study demonstrates the marked abundance of type 1 interferon\u2013inducible transcripts in blood samples from patients with active dermatomyositis, and to a lesser extent polymyositis.","DOI":"10.1002\/art.22928"},{"key":"101_CR26","doi-asserted-by":"crossref","unstructured":"\u2022 Greenberg SA: A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007, 19:536\u2013541. This review outlines how gene expression studies have led to new discoveries in myositis research.","DOI":"10.1097\/BOR.0b013e3282efe261"},{"issue":"Suppl 1","key":"101_CR27","first-page":"S12","volume":"127","author":"B Kea","year":"2007","unstructured":"Kea B, Pesich R, Chung LS, et al.: Genomic analyses identify lipid metabolism abnormalities in dermatomyositis patients [abstract]. J Invest Dermatol 2007, 127(Suppl 1):S12.","journal-title":"J Invest Dermatol"},{"key":"101_CR28","unstructured":"\u2022 Magro CM, Segal JP, Neil Crowson A, Chadwick P: The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2009 Nov 4 (Epub ahead of print). This study demonstrates MxA expression in endothelial cells and keratinocytes in dermatomyositis skin."},{"key":"101_CR29","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","volume":"56","author":"L\u00f3pez Padilla CM de","year":"2007","unstructured":"L\u00f3pez de Padilla CM, Vallejo AN, McNallan KT, et al.: Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007, 56:1658\u20131668.","journal-title":"Arthritis Rheum"},{"key":"101_CR30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel J, Schmidt R, Proelss J, et al.: Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006, 31:576\u2013582.","journal-title":"Clin Exp Dermatol"},{"key":"101_CR31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1600-0560.2007.00848.x","volume":"35","author":"JM McNiff","year":"2008","unstructured":"McNiff JM, Kaplan DH: Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol 2008, 35:452\u2013456.","journal-title":"J Cutan Pathol"},{"key":"101_CR32","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Liao A, Salajegheh M, Morehouse C, et al.: Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin Immunol 2010 Epub ahead of print. Human pDCs become far more efficient producers of type 1 interferons when they accumulate in concentrations exceeding those normally present in blood. This provides a potential mechanism for marked amplification of type 1 interferon\u2013mediated responses in autoimmune disease tissue sites. Blockade of the type 1 interferon receptor is predicted to diminish type 1 interferon production.","DOI":"10.1016\/j.clim.2010.02.014"},{"key":"101_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00403-009-0966-2","volume":"302","author":"SC Chen","year":"2010","unstructured":"Chen SC, de Groot M, Kinsley D, et al.: Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2010, 302:113\u2013123.","journal-title":"Arch Dermatol Res"},{"key":"101_CR34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/DAD.0b013e3181a8527f","volume":"31","author":"N Varughese","year":"2009","unstructured":"Varughese N, Petrella T, Singer M, Carlson JA: Plasmacytoid (CD68 + CD123+) monocytes may play a crucial role in the pathogenesis of hydroa vacciniforme: a case report. Am J Dermatopathol 2009, 31:828\u2013833.","journal-title":"Am J Dermatopathol"},{"key":"101_CR35","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sato S, Hoshino K, Satoh T, et al.: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009, 60:2193\u20132200. Autoantibodies against a type 1 interferon\u2013inducible protein are highly sensitive and specific to clinical amyopathic dermatomyositis across a broad range of rheumatologic diseases. This provides evidence that these autoantibodies are downstream events following type 1 interferon signaling.","DOI":"10.1002\/art.24621"},{"key":"101_CR36","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","volume":"60","author":"AL Mammen","year":"2009","unstructured":"Mammen AL, Casciola-Rosen LA, Hall JC, et al.: Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009, 60:3784\u20133793.","journal-title":"Arthritis Rheum"},{"key":"101_CR37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","volume":"201","author":"L Casciola-Rosen","year":"2005","unstructured":"Casciola-Rosen L, Nagaraju K, Plotz P, et al.: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201:591\u2013601.","journal-title":"J Exp Med"},{"key":"101_CR38","doi-asserted-by":"crossref","unstructured":"\u2022 Indraccolo S, Pfeffer U, Minuzzo S, et al.: Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 2007, 178:1122\u20131135. This study explored the transcriptional effects of interferons on endothelial cells toward a goal of understanding further their antiangiogenic effects.","DOI":"10.4049\/jimmunol.178.2.1122"},{"key":"101_CR39","doi-asserted-by":"crossref","unstructured":"\u2022 Indraccolo S: Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 2010 Feb 19 (Epub ahead of print). The angiogenic and angiostatic effects of interferon-\u03b1 are reviewed.","DOI":"10.3109\/08916930903510963"},{"key":"101_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273\u2013286.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0101-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0101-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T03:30:26Z","timestamp":1635219026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,16]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0101-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,16]]}}}